Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.37% |
| 2 | Consumer Discretionary | 10.36% |
| 3 | Financials | 7.14% |
| 4 | Industrials | 6.8% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
726
Airbnb
ABNB
$112B
| $1.86M | 0.02% |
12,118
+9,459
| +356% | +$1.48M |
|
727
Penumbra
PEN
$12.8B
| $1.85M | 0.02% |
+6,767
| New | +$1.85M |
|
728
Cirrus Logic
CRUS
$5.56B
| $1.85M | 0.02% |
+21,780
| New | +$1.75M |
|
729
Dave & Buster's
PLAY
$355M
| $1.84M | 0.02% |
45,451
+13,539
| +42% | +$586K |
|
730
Flex
FLEX
$40.1B
| $1.83M | 0.02% |
135,984
-101,078
| -43% | -$1.37M |
|
|
RPAI
731
DELISTED
RETAIL PROPERTIES OF AMERICA, INC.
RPAI
| $1.82M | 0.02% |
159,182
+95,312
| +149% | +$1.12M |
|
732
Wendy's
WEN
$1.72B
| $1.82M | 0.02% |
77,809
-504,197
| -87% | -$11.6M |
|
733
SLB Ltd
SLB
$80.1B
| $1.8M | 0.02% |
56,386
-408,406
| -88% | -$12.5M |
|
734
Cognyte Software
CGNT
$628M
| $1.8M | 0.02% |
+73,456
| New | +$1.82M |
|
735
Power Integrations
POWI
$3.01B
| $1.8M | 0.02% |
21,939
+8,903
| +68% | +$719K |
|
736
Fox Class B
FOX
$26.2B
| $1.78M | 0.02% |
50,525
+36,527
| +261% | +$1.32M |
|
737
CALL
Avantor
AVTR
$9.68B
| $1.78M | 0.02% |
+50,000
| New | +$1.62M |
|
|
CXP
738
DELISTED
COLUMBIA PROPERTY TRUST, INC.
CXP
| $1.77M | 0.02% |
102,083
+78,582
| +334% | +$1.42M |
|
739
United Parks & Resorts
PRKS
$2.03B
| $1.77M | 0.02% |
+35,450
| New | +$1.88M |
|
740
Avnet
AVT
$7.11B
| $1.77M | 0.02% |
44,100
+6,328
| +17% | +$272K |
|
741
Ventas
VTR
$48.1B
| $1.76M | 0.02% |
30,894
+11,382
| +58% | +$636K |
|
|
CVA
742
DELISTED
Covanta Holding Corporation
CVA
| $1.76M | 0.02% |
99,815
+33,359
| +50% | +$508K |
|
743
Fortune Brands Innovations
FBIN
$5.45B
| $1.75M | 0.02% |
+20,577
| New | +$1.8M |
|
744
XP
XP
$8.82B
| $1.75M | 0.02% |
+40,153
| New | +$1.66M |
|
745
Immunovant
IMVT
$8.99B
| $1.75M | 0.02% |
+165,417
| New | +$2.31M |
|
746
iShares Russell 1000 Growth ETF
IWF
$125B
| $1.74M | 0.02% |
25,684
+19,644
| +325% | +$1.27M |
|
747
White Mountains Insurance
WTM
$5.12B
| $1.74M | 0.02% |
1,518
-281
| -16% | -$328K |
|
|
SAGE
748
DELISTED
Sage Therapeutics
SAGE
| $1.74M | 0.02% |
30,580
+26,433
| +637% | +$1.87M |
|
749
Ameren
AEE
$29.6B
| $1.74M | 0.02% |
+21,687
| New | +$1.82M |
|
750
Kadant
KAI
$3.6B
| $1.74M | 0.02% |
9,859
+6,397
| +185% | +$1.13M |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.